The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Designing Clinical Trials for Real-World Access
2
Iopofosine I 131 Shows Activity in Post-BTKi Waldenström Macroglobulinemia
3
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5